Quantcast

Latest Exenatide Stories

2014-05-15 08:31:10

TORONTO, May 15, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient in a Phase 2 clinical study of TT-401 (LY2944876), a drug candidate for the treatment of type 2 diabetes. The study is expected to enroll up to 375 type 2 diabetes subjects and will be performed by Transition's development partner, Eli Lilly and Company ("Lilly"). The objectives of the study will be to...

2014-05-07 09:50:08

Follow-up study published in the Journal of Parkinson's Disease supports an earlier 'proof of concept' trial A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers in the Journal of Parkinson's Disease....

2014-04-17 23:01:33

The Firm is actively evaluating Byetta lawsuit claims on behalf of diabetics who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer after taking the incretin mimetic. New York, NY (PRWEB) April 17, 2014 More than 30 federal cases have joined a federal diabetes drug litigation that includes an increasing number of Byetta lawsuit (http://www.byettalawsuit.com/) filings, as well as claims over similarly-designed medications, Bernstein Liebhard LLP reports. Court documents...

2014-04-01 08:28:59

-Promising first interim phase 3 data for ITCA 650 in type 2 diabetes, combined with robust execution against key milestones and the addition of key talent BOSTON, April 1, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the completion of another landmark private round of equity financing for $200 million. Together with the $210 million round of equity and debt financing in November of 2012 the company is very strongly positioned for future milestones and launch...

2014-03-29 23:01:26

The Firm is investigating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of Byetta. New York, New York (PRWEB) March 29, 2014 As Byetta lawsuits (http://www.byettalawsuit.com) continue to move forward in federal court, Bernstein Liebhard LLP notes that a newly published study is raising questions about the costs and benefits associated with newer medications used in the treatment of Type 2 diabetes....

2014-03-22 23:02:37

The Firm is currently offering free and confidential Byetta lawsuit evaluations to individuals who may have developed pancreatic cancer, pancreatitis or thyroid cancer after taking the Type 2 diabetes medication. New York, NY (PRWEB) March 22, 2014 A year after the U.S. Food and Drug Administration (FDA) publicly vowed to investigate the safety of a drug now involved in Byetta lawsuit (http://www.byettalawsuit.com/) filings, as well as several other Type 2 diabetes medications, court...

2014-03-11 08:30:59

JERUSALEM, March 11, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office, has issued the Company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's...

2014-03-10 23:27:46

National network of lawyers continues offer of complimentary consultations to consumers seeking compensation in lawsuits alleging links between diabetes medications Byetta, Januvia, Janumet and Victoza and pancreatic cancer. San Diego, CA (PRWEB) March 10, 2014 http://www.resource4thepeople.com/defectivedrugs/byetta.html Resource4thePeople announced today its latest update for consumers following allegations in lawsuits* claiming that the use of the diabetes medication Byetta and other...

2014-03-03 08:32:04

Podium Presentation Highlighting Safety and Efficacy Data to be Presented by the Company's CSO, Dr. Miriam Kidron JERUSALEM, March 3, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule...

2014-03-01 23:01:16

The Firm is actively investigating Byetta lawsuit claims on behalf of diabetics who may have been diagnosed with pancreatitis, pancreatic cancer or thyroid cancer after taking the medication. New York, New York (PRWEB) March 01, 2014 The federal litigation of Byetta lawsuits (http://www.byettalawsuit.com/) and other claims involving similar Type 2 diabetes drugs has grown to include more than 300 cases, Bernstein Liebhard LLP reports. According to a Case List updated February 19th by the...


Latest Exenatide Reference Libraries

36_67c6fec75293d7e1e91a0c52aa692cf7
2005-06-22 14:17:05

The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...

More Articles (1 articles) »
Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related